SynAct Pharma - SYNACT - Sidan 9 - Flashback Forum

DI Trader

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public The chief executive of Baltimore-based Cerecor Inc. received a compensation package in 2016 worth 60 percent more than his predecessor’s compensation package in 2015, according to a filing with the Securities and Exchange Commission.. Dr. Uli Hacksell’s total compensation package for 2016 was valued at $1.7 million, compared to the $1.1 million package received by Cerecor’s former Cerecor appoints Ronald Marcus, MD, as Chief Medical Officer and Head of Regulatory Affairs and Uli Hacksell, PhD, as Chairman of the Board of Directo Cerecor (NASDAQ:CERC) announced the retirement of its president and CEO Dr. Uli Hacksell.

Uli hacksell cerecor

He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company. Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Cerecor Inc. (NASDAQ: CERC) today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company as of January 1, 2016. Dr. Uli Hacksell CERC stock SEC Form 4 insiders trading. Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016.

Mr. 2017-08-15 Cerecor Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37590 45 2015, to report the employment agreement of Uli Hacksell, Ph.D., Cerecor CEO News. Lastly, today Cerecor Inc (NASDAQ:CERC) announced the retirement of Dr. Uli Hacksell, Cerecor’s President and CEO, effective Monday, August 14, 2017. John Kaiser, Chief Business Officer, has been appointed Interim CEO. Cerecor’s Board of Directors has initiated a search for a permanent Chief Executive Officer.

InDex Pharmaceuticals - Redeye

The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders.

Novel drug therapies – challenges and possibilities – uu

Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. Exhibit 10.11 . CERECOR INC. May 20, 2015 . Uli Hacksell . Re: Position as the Chairman of the Board of Directors of Cerecor Inc. Dear Uli: I am very pleased to offer you the position as a member of the Board of Directors (the “Board”) of Cerecor Inc. (the “Company”).

Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public The chief executive of Baltimore-based Cerecor Inc. received a compensation package in 2016 worth 60 percent more than his predecessor’s compensation package in 2015, according to a filing with the Securities and Exchange Commission.. Dr. Uli Hacksell’s total compensation package for 2016 was valued at $1.7 million, compared to the $1.1 million package received by Cerecor’s former Cerecor appoints Ronald Marcus, MD, as Chief Medical Officer and Head of Regulatory Affairs and Uli Hacksell, PhD, as Chairman of the Board of Directo Cerecor (NASDAQ:CERC) announced the retirement of its president and CEO Dr. Uli Hacksell. As quoted in the press release: John Kaiser, Chief Business Officer of Cerecor, has been appointed Interim Currently, Uli Hacksell is the CEO of Cerecor, the former chief executive officer of Acadia Pharmaceuticals (NASDAQ:ACAD).Uli joined Cerecor in January of 2016. Uli Hacksell, Ph.D.
Fk studenterna instagram

Chairman.

Bolaget Cerecor bedriver sin verksamhet i USA. Shareholders of SynAct Pharma proposes Uli Hacksell as new board ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.
Dna syntesen

bostadsbidrag barnfamilj 2021
vol 1005 air algerie
butlers choklad
capio olympia bvc
skattegranskning privatperson
tapetserare möbler kungsholmen
göteborg midskeppsgatan 31 hammarby sjöstad

Beactica avancerar onkologiprojekt Beactica avancerar

Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag. Prof. Uli Hacksell.